ABBV Abbvie Inc

What’s closest to your #preferred #tempo of #pharma or #biotech #commercials #ads #ad #commercial ? $ABBV $REGN $NVS $OTLK #HEALTHCARE

$ABBV $BMY $SLS Greg, last 2 patients to hit 80 Events is coming from GPS 48 Patients that are functionally CURED. Now that is why I have been saying that don’t be surprised if there is a halt for efficacy by IDMC. All things are possible here at this point in time.✌️🙏❤️‍🩹

$ABBV its struggling with that 267 mark. Maybe a quick trip to the 250s and we'll try again in a month or so

$abbv Investment bank Wells Fargo set a 12-month price target for pharmaceutical company AbbVie of $300 on Thursday, giving the Chicago-based company an overweight rating, which is equivalent to a buy. Analyst Mohit Bansal said the AbbVie has solid patent protection for its core business units and that he is expecting updates on the firm’s work in oncology and neuroscience. “We rate ABBV Overweight, as we think that the stock is reasonably priced for strong growth into the next decade, coupled with long-term patent protection for key businesses. We expect mid-stage pipeline to come to limelight in next 12 months, which should help with multiple expansion,” https://www.cnbc.com/2026/09/10/stock-market-today-live-updates.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension

🚀 $ABBV 09/04 $272.50 CALL @ $0.14 🔥 HIGH-RISK LOTTO — THIS COULD RUN BIG! 📦 1,000 CONTRACTS 👀 WATCHING THIS ONE CLOSELY

$ABBV 🔻 📅 28 AUG 26 — $257.5 PUT 💰 Entry: $1.04 📊 FOUR-DAY INSIDE BAR 🎯 HIGH-CONFIDENCE SETUP 🔥 ⚡️ WATCHING FOR THE BREAKDOWN 📉

$ABBV It is not a lot but I bought 25 shares in the last 2 month. I think this will pay out.

$ABBV AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign Wake me up under $250 !!

$ABBV The BCLI narrative is only about the trial but the numbers are so much worse. RMTG is just showing profits .

$ABBV per previous convos. Follow me for more random thoughts that might make you some money, will probably lose you some money

🔔 IF YOU’RE SERIOUS ABOUT TRADING, TAP IN. 💎 I’ve been sharing some of my best setups inside my Telegram community — trades and market plays that I don’t always post here on Stocktwits. 📲🔥 📈 THIS WEEK’S RESULTS: $ABBV PUTS — +246% 💎 $DE CALLS — +234% 💎 $MSFT CALLS — +190% 💎 $DE CALLS — +182% 💎 $BE CALLS — +141% 💎 👑 2 × 230%+ GAINERS 👑 5 × 100%+ GAINERS I’m not here to chase every move. I’m looking for the setups that make sense and getting positioned early. If you want to follow along, the Telegram link is in my bio. 📲🔥 STAY LOCKED IN. 👀💎

$ABBV Expect stock pressure but doubt it goes below $100. Then, you'll see a couple of days of substantial moves higher then a buyout. Likely Oct/Nov time frame.

$ABBV UPDATE 🚨 ABBV is showing some weakness today, currently around $258.68 (-1.61%). Key level: $260 👀 If ABBV can reclaim and hold $260, I’d want to see buyers push it back toward $261–$263. If it continues trading below $260, especially if $258 breaks, momentum could remain bearish. ⚠️ Don’t chase the move. I want confirmation before calling the reversal. Bullish above $260 📈 | Bearish below $258 📉 Watching closely. 🔥

🚨 $ABBV UPDATE 🚨 ABBV is pulling back after getting rejected around the $266 area. But here’s the important part: the company’s fundamentals remain strong. 📊 Q2 revenue: $16.99B (+10.2% YoY) 💰 Adjusted EPS: $3.65 🔥 Skyrizi: +24% 🔥 Rinvoq: +24% ⚠️ Humira: -35.9% AbbVie also raised its 2026 revenue outlook to roughly $67.6B, while slightly lowering EPS guidance because of the Apogee acquisition. For the chart, I’m watching $266–$267.47 as the key upside zone. If ABBV reclaims that area with volume, momentum could strengthen. If it keeps losing support instead, I want to see stabilization before calling a reversal. Strong company ≠ automatic bullish trade. Let price confirm. 📈

$ABBV $IHE $XLV ABBV continues to exhibit constructive post-breakout behavior following its successful reclaim and acceptance above the $236 resistance level. The subsequent consolidation and rounding pattern served to retest support without materially damaging the bullish structure, while momentum remained firmly in a bullish regime. More recently, price has achieved acceptance above the $260-$261 resistance area, suggesting buyers have absorbed another layer of overhead supply. Taken together, the evidence supports an ongoing bullish intermediate-term trend characterized by successful breakout retention, improving support structure, and momentum confirmation.